DXSE:XETRA:XETRA-Xtrackers - Stoxx Europe 600 Health Care Swap UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 212.95

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

465.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

+0.48 (+1.06%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.13 (+0.14%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.25 (+1.06%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

+0.17 (+1.30%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

+0.07 (+1.32%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

+0.28 (+1.21%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

-0.01 (-0.05%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

+1.35 (+2.43%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

+0.02 (+0.21%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

+0.08 (+0.06%)

USD 12.26B

ETFs Containing DXSE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.02% 54% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.02% 57% F 53% F
Trailing 12 Months  
Capital Gain -4.70% 17% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.70% 20% F 26% F
Trailing 5 Years  
Capital Gain 28.81% 39% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.81% 40% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain 9.61% 64% D 64% D
Dividend Return 9.61% 63% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.74% 67% D+ 74% C
Risk Adjusted Return 109.95% 94% A 94% A
Market Capitalization 0.14B 45% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.